Independent equity research
Is Laboratorios Farmacéuticos Rovi, S.A. (ROVI) a Buy, Hold or Sell?
Laboratorios Farmacéuticos Rovi, S.A. — our independent, AI-built valuation and rating, in brief.
HOLD (reduce into strength)
12-mo fair value
€53.96
To fair value
−9%
By · report dated 2026-09-20 · fair value derived independently of the market price.
The thesis, in brief
At €57.65 ROVI prices a faster CDMO ramp than we model: with Neparvis lapsing in October and the April-2024 syringe contract slipping into 2027, we see 2027E canonical EBITDA of €208m against a €263m consensus; a 2027 print above €240m, or routine PFS supply before mid-2027, would prove us wrong
How we value it
We value Laboratorios Farmacéuticos Rovi, S.A. using Scenario-weighted FCFF DCF (25/50/25) at 7.9% WACC, 2.0% terminal growth, 7-yr. The 12-month fair value is set from that intrinsic estimate first, then compared to the market to read the upside or downside — never anchored to the current price.
What the full report covers
- Business & moat + industry cycle
- Earnings quality & normalized EPS
- Returns on capital (ROIC vs WACC)
- Balance-sheet safety
- Two independent valuations (DCF + multiples)
- Bear / base / bull fair values
- Earnings-call analysis
- Insider activity & positioning
- Technicals (RSI / ADX)
- A falsifiable thesis
Read the full Laboratorios Farmacéuticos Rovi, S.A. report
The complete model, the scenarios, and every number behind the call — plus other names across the coverage. One subscription, cancel anytime.